Roth Capital Issues Pessimistic Estimate for NAGE Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Equities research analysts at Roth Capital lowered their FY2026 EPS estimates for Niagen Bioscience in a report released on Wednesday, October 1st. Roth Capital analyst S. Mcgowan now anticipates that the company will earn $0.12 per share for the year, down from their previous forecast of $0.13. Roth Capital has a “Buy” rating and a $23.00 price objective on the stock.

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. HC Wainwright lifted their price target on Niagen Bioscience from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, August 11th. Canaccord Genuity Group boosted their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, June 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Saturday, September 27th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Niagen Bioscience presently has an average rating of “Moderate Buy” and an average price target of $13.42.

Niagen Bioscience Price Performance

Shares of NASDAQ:NAGE opened at $6.93 on Friday. Niagen Bioscience has a 12 month low of $3.18 and a 12 month high of $14.69. The firm has a market capitalization of $552.67 million, a P/E ratio of 33.00 and a beta of 2.13. The company’s fifty day moving average price is $9.57 and its 200 day moving average price is $9.48.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The business had revenue of $31.12 million during the quarter, compared to the consensus estimate of $28.55 million.

Hedge Funds Weigh In On Niagen Bioscience

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its position in Niagen Bioscience by 89.5% during the 4th quarter. Bank of America Corp DE now owns 52,144 shares of the company’s stock worth $277,000 after buying an additional 24,622 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Niagen Bioscience in the fourth quarter valued at about $675,000. Finally, Millennium Management LLC acquired a new position in shares of Niagen Bioscience during the fourth quarter worth about $1,199,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.